Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results